Navigation Links
12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system)

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plc announced that DAYTRANA(TM) (methylphenidate transdermal system), the first and only non-oral medication approved for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association (APA) annual meeting in San Diego.

"We documented that children with ADHD experienced effective ADHD treatment with use of DAYTRANA for 12 months, sustaining the improvements in their ability to maintain focus and concentration," said investigator Oscar Bukstein, M.D., Associate Professor of Psychiatry, University of Pittsburgh School of Medicine. "More importantly, Daytrana maintained a favorable safety profile, meeting the study's primary endpoint, and demonstrating an incidence of adverse events that is consistent with previous trials and other stimulants in this class."

Shire's DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. DAYTRANA is available in four dosage strengths - 10 mg, 15 mg, 20 mg and 30 mg - all designed for once-daily use. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage the potential for late-day side effects.

Bukstein added, "DAYTRANA's novel patch delivery system offers physicians and parents of children with ADHD a convenient, non-oral option to individualize ADHD treatment to meet their children's changing schedules."

This study was an open-label extension of four
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:7/22/2008)...pment Plan Completed Successfully, DUBLIN, Irelan...ation,plc (NASDAQ: AMRN ) today announced that th...Food and Drug Administration (FDA) to discuss the,...t of,hypertriglyceridemia. Following these discuss...R101 in hypertriglyceridemia., Dr. Declan Doogan,...
(Date:7/22/2008)...and Apidra(R) Resulted in Significant, Reductions ...the Algorithm Use...ults from the "Adjust to,Target in Type 2 Diabetes...,Counting for Adjustment of Mealtime Insulin Gluli...es Association,s (ADA) medical journal,Diabetes C...
(Date:7/22/2008)...herapy and pegylated enzyme produces significan...ne - - Pegylated enzyme well tole.../ -- Halozyme Therapeutics,Inc. (Nasdaq: HALO ),...cializing products targeting the extracellular mat...pre-clinical animal efficacy data,for its pegylate...
(Date:7/22/2008)...2 /- NicOx S.A.,(Euronext P...pleted the,enrollment of 417 osteoarthritis (OA) p...al pharmacology studies in the United States, in l...als are designed to assess the,blood pressure prof...,naproxen, using the Ambulatory Blood Pressure Mon...
Breaking Medicine Technology:Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Mayo Researchers Say ECG Standards Should Be Revised for Elderly 14432 1Mayo Researchers Say ECG Standards Should Be Revised for Elderly 14432 2CryoCor Announces Web cast and Conference Call of 2007 Year End Results 14427 1CryoCor Announces Web cast and Conference Call of 2007 Year End Results 14427 2Obesity Linked to Poor Prognosis for Some Breast Cancer Patients 14425 1Obesity Linked to Poor Prognosis for Some Breast Cancer Patients 14425 2Obesity Linked to Poor Prognosis for Some Breast Cancer Patients 14425 3Free Egg Donor Contest Ending March 31 14421 1Free Egg Donor Contest Ending March 31 14421 2
(Date:7/25/2008)... Whether you are an Olympian, Professional ...re Five Things You Need to Know about Hydration to... and Sports Center , Mari...a,s premier athletes are heading to Beijing follow...crifice in the hopes of capturing an Olympic medal...
(Date:7/25/2008)... This donation will be used to facilitate t...es for children , Hauppau...ci.com ), a leading integrator of enterprise coll...o conferencing, telepresence, audio visual integra... today that it has donated video conferencing equi...
(Date:7/24/2008)..., N.C. Researchers at Wake Forest University Bap... clinical belief that the hepatitis C virus slows ...tself after HIV patients are treated with a combin...itis C (HCV) infection is more serious in HIV-infe...ing to the Centers for Disease Control. Intravenou...
(Date:7/24/2008)...ly 24 /PRNewswire-USNewswire/ -- Speaker Nancy Pel...in support of the Tom Lantos,and Henry J. Hyde Glo...,Malaria Reauthorization Act of 2008. The bill, wh...this evening by a vote of 303 to 115 and will now ...day the House took an historic vote to pass landma...
Breaking Medicine News(10 mins):Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2
...treating tissue at the back of the mouth is succes...en and 30 per cent of women have a problem with sn...em is vibrations in the soft palate - the area of ...la, the sides of the tonsils, and the base of the ...
...ften have gastrointestinal symptoms such as incont...frequent stomach and intestinal troubles may be a ...a side effect of diabetes medications, researchers...tburn, bloating, nausea, vomiting, diarrhea and co...
...tember 11 terrorist acts in New York and Washingto...put on hold for several days, which severely affec...ceuticals. Most radiopharmaceuticals are shipped v...hese products are either radioactive themselves or...
... Administration has approved the first hormone-rel...ganon, Inc., effectively blocks conception between...that for every 100 women who use it for a year, on... That rate is similar to both the birth control pi...
Other Medicine News:
... OPMI Vario/NC33 System, Carl Zeiss has successful...et. , ,The success of this instrument is by n...ct and stylish design. Maximum ergonomic convenien...n to be used with a surgical microscope, allowing ...
...g; Suction Punch Forceps provide superior tissue e.... Shutt® Suction Graspers offer an aggressive ...he jaws. Both feature a unique stress pin bufferin...In use, the stress pin buffering system applies in...
Leg holder for arthroscopy.
Osteoprep instruments provide an array of bone shaping devices especially suited for notchplasties.
Medicine Products: